Raquel Aloyz

Lady Davis Institute for Medical Research

Affiliated withLady Davis Institute for Medical Research McGill University

Research Area

Biology

Biography

Raquel Aloyz has not added Biography.
If you are Raquel Aloyz and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title	2025

Other Publications

Article	Year
The role of DNA repair in nitrogen mustard drug resistance. Anti-cancer drugs\| PubMed ID: 11984064	2002
Homologous recombinational repair vis-à-vis chlorambucil resistance in chronic lymphocytic leukemia. Biochemical pharmacology\| PubMed ID: 12007561	2002
DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anti-cancer drugs\| PubMed ID: 12045463	2002
Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer research\| PubMed ID: 12359753	2002
Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis. The Journal of pharmacology and experimental therapeutics\| PubMed ID: 15843498	2005
Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair vi... The Journal of pharmacology and experimental therapeutics\| PubMed ID: 17351105	2007
XRCC3 depletion induces spontaneous DNA breaks and p53-dependent cell death. Cell cycle (Georgetown, Tex.)\| PubMed ID: 17351336	2007
Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. British journal of haematology\| PubMed ID: 19062342	2008
Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma. Leukemia research\| PubMed ID: 19758698	2010
Vav-1 expression correlates with NFκB activation and CD40-mediated cell death in diffuse large B-cell lymphoma cell lines. Hematological oncology\| PubMed ID: 20155735	2010
p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes. Leukemia research\| PubMed ID: 20573397	2011
A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients. Cancer chemotherapy and pharmacology\| PubMed ID: 21120481	2011
Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond. Frontiers in pharmacology\| PubMed ID: 23386830	2013
Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition. Blood cancer journal\| PubMed ID: 29367649	2018
PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines. Breast cancer research and treatment\| PubMed ID: 30039287	2018
Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes. Frontiers in oncology\| PubMed ID: 30319974	2018
Metabolic rewiring beyond Warburg in chronic lymphocytic leukemia: How much do we actually know? Critical reviews in oncology/hematology\| PubMed ID: 30771875	2019
Bruton's tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes. Scientific reports\| PubMed ID: 31363127	2019
Using Two Peptide Isotopologues as Internal Standards for the Streamlined Quantification of Low-Abundance Proteins by Immuno-MRM and Immuno-MALDI. Analytical chemistry\| PubMed ID: 32786432	2020
EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax. Journal of experimental & clinical cancer research : CR\| PubMed ID: 36482393	2022
PARP Inhibition Sensitizes Breast Cancer Cells to Eribulin. Frontiers in bioscience (Landmark edition)\| PubMed ID: 37005765	2023
Translational control of leukemic metabolism and disease progression. Trends in cell biology\| PubMed ID: 40410003	2025